BS_A3QZB9Y2
Meningioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Meningioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Meningioma
- overall_survival_months
- 136.00525624178712
- age_years
- 12.589
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.584
- ALLOGRAFT_REJECTION+0.484
- INTERFERON_GAMMA_RESPONSE+0.474
- IL6_JAK_STAT3_SIGNALING+0.424
- OXIDATIVE_PHOSPHORYLATION+0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.385
- APICAL_SURFACE+0.372
- INFLAMMATORY_RESPONSE+0.356
- PI3K_AKT_MTOR_SIGNALING+0.333
- NOTCH_SIGNALING+0.276
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.329
- HEDGEHOG_SIGNALING-0.294
- SPERMATOGENESIS-0.197
- KRAS_SIGNALING_DN-0.180
- MYC_TARGETS_V2-0.110
- BILE_ACID_METABOLISM-0.107
- UV_RESPONSE_UP-0.094
- WNT_BETA_CATENIN_SIGNALING-0.075
- HYPOXIA-0.032
- HEME_METABOLISM-0.029
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_QW60M0FE | Meningioma | — | 0.921 |
| 2 | BS_W72364MN | Meningioma | — | 0.919 |
| 3 | BS_JGPR9SR2 | Meningioma | — | 0.901 |
| 4 | BS_X2QTK3QD | Meningioma | — | 0.901 |
| 5 | SJBT031026_D3.RNA-Seq | EPN | Spinal EPN | 0.860 |
| 6 | SRR934884 | — | — | 0.857 |
| 7 | BS_Z9ZS6ZS2 | MPNST | — | 0.849 |
| 8 | BS_JK0VPG1T | Schwannoma | — | 0.848 |
| 9 | SRR12696731 | — | — | 0.844 |
| 10 | BS_HBJZR69P | Schwannoma | — | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.584 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.484 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.474 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.424 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.390 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.385 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.372 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.356 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.333 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.276 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.273 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.266 | Idelalisib | — uncovered |
| APOPTOSIS | 0.265 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.220 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.214 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.213 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.203 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.199 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.199 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.197 | Inavolisib | — uncovered |